FTC Dispute Helps to Explain Rising Medical Device Costs

The FTC recently challenged over 100 patents in the FDA’s Orange Book, a guide that lists drug products, patents, and viable generics. A patent in the Orange Book for pharmaceutical companies delays competitors from entering the market because of infringement risks. However, the FTC found several instances of medical device patents listed in the Orange Book that overstep the Book’s purpose. These improper patents are artificially extending monopolies to pharmaceutical companies. This adds to the rising costs of inhalers and EpiPens, which come at the consumer’s expense.

View More FTC Dispute Helps to Explain Rising Medical Device Costs

Abortion Pill Rulings Leave the FDA in Political Crossfire

This month, FDA approval of mifepristone, a key drug used for medication abortion, has been the subject of several federal rulings. Representatives of the FDA and private drug companies have spoken out against the motion to overrule FDA approval, citing extensive safety data. Depending on the decision from the Supreme Court, these rulings could set a new precedent allowing federal courts to overturn FDA approval.

View More Abortion Pill Rulings Leave the FDA in Political Crossfire

Martin Shkreli Returns as Drug Prices Continue to Rise

Martin Shkreli became the internet’s most hated man in 2015 for hiking the price of life-saving medicine and mocking his online critics. Last month, Shkreli returned to the headlines when he started a new drug discovery company. As the FTC cracks down on Shkreli’s business, drug prices continue to rise.

View More Martin Shkreli Returns as Drug Prices Continue to Rise